MilliporeSigma, the life-sciences business of Merck KGaA, has opened a new joint process scale-up laboratory in Bangalore (i.e., Bengaluru), India to provide end-to-end solutions for biologics from process development to scale-up and manufacturing for preclinical, clinical, and commercial supply 

The lab is located at the research and development (R&D) facility in Bangalore of Stelis Biopharma, a vertically integrated biopharmaceutical company offering R&D, process scale-up, and end –to- end manufacturing capabilities from drug substance to finished drug products in all injectable formats. The lab was built as a center of excellence for process scale-up and manufacturing services. The collaboration brings together Stelis’ end-to-end capabilities in bioprocess development from cell line to commercial manufacturing scale and MilliporeSigma’s technological expertise in bioprocessing.

The lab and a soon-to-be-completed cGMP manufacturing facility will house MilliporeSigma’s portfolio of Mobius bioprocessing equipment and single-use manufacturing components. MilliporeSigma will provide process know-how and application knowledge to help establish the single-use platform technologies at Stelis as part of the collaboration.

Stelis has a 30,000-square-foot research facility in Bangalore with a soon-to-be commissioned 200,000- square-foot integrated biomanufacturing facility for biologic active pharmaceutical ingredients and aseptically filled injectables The principal shareholders of Stelis are Strides Pharma, Tenshi Life Sciences Private Limited, and GMS Holdings.

Source: Merck KGaA